Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK plus NSCLC Leal, T., Wakelee, H., Infante, J., Blumenschein, G., Reckamp, K., Carter, C., Waqar, S., Gockerman, J., Lovly, C., Dukart, G., Harrow, K., Liang, C., Gibbons, J., Horn, L. ELSEVIER SCIENCE INC. 2016: S176–S177

View details for Web of Science ID 000427345100013